Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
$78,000 |
 |
AmarinAMRN |
$410,000 |
 |
Gilead SciencesGILD |
-$1.21B |
 |
Anavex Life SciencesAVXL |
-$6.3M |
 |
AmgenAMGN |
-$98M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Wood Gavin | Sep 2, 2025 | Sell | 96,000 | $0.0099 | $950 |
| Bertrand William C JR | Aug 28, 2025 | Sell | 207,000 | $0.0101 | $2,100 |
| Behbahani Ali | Aug 18, 2025 | Sell | 14,671,794 | $0.012 | $180,000 |
| Behbahani Ali | Aug 15, 2025 | Sell | 4,828,206 | $0.011 | $53,000 |
| EcoR1 Capital, LLC | Jul 30, 2025 | Sell | 27,433,338 | $0.1021 | $2.8M |
| EcoR1 Capital, LLC | Jul 29, 2025 | Sell | 2,687,460 | $0.1012 | $270,000 |
| EcoR1 Capital, LLC | Jul 28, 2025 | Sell | 33,931,740 | $0.1125 | $3.8M |
| Rawcliffe Adrian | Jan 17, 2025 | Sell | 30,601 | $0.5808 | $18,000 |
| Norry Elliot | Jan 17, 2025 | Sell | 5,584 | $0.5808 | $3,200 |
| Lunger John | Jan 17, 2025 | Sell | 5,584 | $0.5808 | $3,200 |
| Bertrand William C JR | Jan 17, 2025 | Sell | 5,584 | $0.5808 | $3,200 |
| Rawcliffe Adrian | Jan 15, 2025 | Sell | 29,096 | $0.5748 | $17,000 |
| Piccina Cintia | Jan 15, 2025 | Sell | 12,991 | $0.5748 | $7,500 |
| Norry Elliot | Jan 15, 2025 | Sell | 9,803 | $0.5748 | $5,600 |
| Lunger John | Jan 15, 2025 | Sell | 9,803 | $0.5748 | $5,600 |
| Bertrand William C JR | Jan 15, 2025 | Sell | 9,803 | $0.5748 | $5,600 |
| Rawcliffe Adrian | Jan 13, 2025 | Sell | 17,934 | $0.5879 | $11,000 |
| Rawcliffe Adrian | Jan 13, 2025 | Sell | 12,539 | $0.5879 | $7,400 |
| Norry Elliot | Jan 13, 2025 | Sell | 8,124 | $0.5879 | $4,800 |
| Norry Elliot | Jan 13, 2025 | Sell | 4,268 | $0.5879 | $2,500 |
| Lunger John | Jan 13, 2025 | Sell | 5,471 | $0.5879 | $3,200 |
| Lunger John | Jan 13, 2025 | Sell | 4,268 | $0.5879 | $2,500 |
| Bertrand William C JR | Jan 13, 2025 | Sell | 5,471 | $0.5879 | $3,200 |
| Bertrand William C JR | Jan 13, 2025 | Sell | 4,268 | $0.5879 | $2,500 |
| Piccina Cintia | Jun 18, 2024 | Sell | 24,531 | $0.93 | $23,000 |
| Rawcliffe Adrian | Jan 17, 2024 | Sell | 30,080 | $0.673 | $20,000 |
| Norry Elliot | Jan 17, 2024 | Sell | 12,967 | $0.673 | $8,700 |
| Lunger John | Jan 17, 2024 | Sell | 12,805 | $0.673 | $8,600 |
| Bertrand William C JR | Jan 17, 2024 | Sell | 13,599 | $0.673 | $9,200 |
| Norry Elliot | Jan 17, 2024 | Sell | 5,309 | $0.673 | $3,600 |
| Lunger John | Jan 17, 2024 | Sell | 5,309 | $0.673 | $3,600 |
| Bertrand William C JR | Jan 17, 2024 | Sell | 5,309 | $0.673 | $3,600 |
| Rawcliffe Adrian | Jan 16, 2024 | Sell | 9,304 | $0.79 | $7,400 |
| Norry Elliot | Jan 16, 2024 | Sell | 2,287 | $0.79 | $1,800 |
| Lunger John | Jan 16, 2024 | Sell | 4,681 | $0.79 | $3,700 |
| Bertrand William C JR | Jan 16, 2024 | Sell | 4,681 | $0.79 | $3,700 |
| Rawcliffe Adrian | Jan 12, 2024 | Sell | 17,257 | $0.8541 | $15,000 |
| Bertrand William C JR | Jan 12, 2024 | Sell | 5,220 | $0.8541 | $4,500 |
| Lunger John | Jan 12, 2024 | Sell | 5,220 | $0.8541 | $4,500 |
| Norry Elliot | Jan 12, 2024 | Sell | 7,799 | $0.8541 | $6,700 |
| Rawcliffe Adrian | Jan 11, 2024 | Sell | 11,945 | $0.8367 | $10,000 |
| Bertrand William C JR | Jan 11, 2024 | Sell | 4,009 | $0.8367 | $3,400 |
| Lunger John | Jan 11, 2024 | Sell | 4,009 | $0.8367 | $3,400 |
| Norry Elliot | Jan 11, 2024 | Sell | 4,009 | $0.8367 | $3,400 |
What's the latest insider transaction for Adaptimmune Therapeutics?
The most recent insider transaction for Adaptimmune Therapeutics was conducted by Wood Gavin, who sold 96,000 shares on September 2, 2025 at a price of $0.01 per share.
Which insider has sold the most ADAP stock over the last two years?
EcoR1 Capital, LLC has sold the most ADAP stock in the last 2 years, with a total value of $6.9M.
What is the total value of insider transactions for Adaptimmune Therapeutics (ADAP) in the last 2 years?
The total value of insider transactions for Adaptimmune Therapeutics in the last 2 years is negative, amounting to -$7.4M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Adaptimmune Therapeutics' market confidence?
Over the last 2 years, insider transactions for Adaptimmune Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
